First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Eligible patients were aged ≥65 years, or <65 years with...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno, Carol, Greil, Richard, Demirkan, Fatih, Tedeschi, Alessandra, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Novak, Jan, Strugov, Vladimir, Gill, Devinder, Gribben, John G., Kwei, Kevin, Dai, Sandra, Hsu, Emily, Dean, James P., Flinn, Ian W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Chronic Lymphocytic Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425310/
https://www.ncbi.nlm.nih.gov/pubmed/35021599
http://dx.doi.org/10.3324/haematol.2021.279012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425310/
https://www.ncbi.nlm.nih.gov/pubmed/35021599
http://dx.doi.org/10.3324/haematol.2021.279012

Ejemplares similares